CRBU - CIK 0001619856
The table below shows Caribou Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$110.99M | -$138.20M | -$93.29M | -$90.97M | -$32.52M | -$33.22M |
| Capital expenditure | $1.36M | $4.88M | $11.61M | $6.45M | $2.12M | $317.00K |
| Investing cash flow | $102.24M | $86.61M | -$68.18M | -$93.25M | -$176.40M | $6.36M |
| Dividends paid | - | - | - | - | - |
Caribou Biosciences, Inc. reported operating cash flow of -$110.99M for fiscal year 2025. That is up 19.7% from -$138.20M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$32.01M (FY 2019) to -$110.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.82M | $16.72M | $154.30M | $2.13M | $433.43M | $1.74M |